



## **Living Cell Technologies Limited**

**ACN:** 104 028 042  
**ASX:** LCT  
**OTCQX:** LVCLY

### **ASX ANNOUNCEMENT**

## **Change of Registered Office Address**

---

**19 January 2015**

As of 19 January 2015 the Registered Office address of the company will change to:

**Suite 806, Level 8**

**70 Pitt Street**

**SYDNEY NSW 2000**

**Phone numbers remain unchanged:**

**Tel: +61 2 9239 0277 or 1300 134 875 (within Australia)**

**Fax: 9233 4497**

The mailing address – GPO Box 4231, Sydney NSW 2001 also remains the same.

By order of the Board

A handwritten signature in black ink, appearing to read 'Nick Geddes', with a horizontal line underneath.

Nick Geddes  
Company Secretary

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

<p><b>At the company:</b>  Ken Taylor  Chief Executive  Tel: +64 9 276 2690  Mobile: +64 21 796000  <a href="mailto:ktaylor@lctglobal.com">ktaylor@lctglobal.com</a></p>	<p><b>Media enquires:</b>  Rachael Joel  Botica Butler Raudon Partners  Tel: +64 9 303 3862  Mobile: +64 21 403 504  <a href="mailto:rachaelj@botica.co.nz">rachaelj@botica.co.nz</a></p>
--	---

## About Living Cell Technologies

Living Cell Technologies (LCT) is an Australasian biotechnology company researching and developing cell therapies to treat diseases with high unmet clinical need. LCT's lead product NTCELL<sup>®</sup> is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing factors to promote new central nervous system growth and repair disease induced nerve degeneration.

NTCELL is in Phase I/IIa clinical trial in New Zealand for the treatment of Parkinson's disease. It has the potential to be used in a number of other central nervous system indications such as Huntington's, Alzheimer's and motor neurone diseases.

LCT's proprietary encapsulation technology, IMMUPEL<sup>™</sup>, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter

## LCT disclaimer

*This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential", "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking*

*statements contained in this document as a result of new information, future events or developments or otherwise.*